openPR Logo
Press release

Computed Tomography to Drive The Orally Disintegrating Tablet Market

02-22-2022 10:39 AM CET | Health & Medicine

Press release from: Persistence Market Research

Computed Tomography to Drive The Orally Disintegrating Tablet

The Orally Disintegrating Tablet Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.

Improvements in drug delivery mechanism offering quicker onset of action with superior bioavailability per dose have transformed characteristics of orally administered drugs with the development of orally disintegrating tablets (ODTs). The global orally disintegrating tablets market was valued at nearly US$ 12 Bn in 2018 and will exhibit a solid CAGR during the forecast period (2019 - 2029).

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14572

There has been growing preference among consumers and patients for orally disintegrating tablets attributed to increasing applications in treatment of diseases related to central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders, and allergy. Bayer's acquisition of Merck's consumer care unit was aimed at gaining shares in ODTs. Claritin, an ODT received through this acquisition, was the largest revenue generating drug for allergy in the U.S. that year.

Company Profiles:

Teva Pharmaceutical Industries Ltd.
Novartis AG
AstraZeneca
Mylan N.V.
Pfizer Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bausch Health
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Bayer AG
Eli Lily and Company
Dr. Reddy's Laboratories Ltd.
Takeda Pharmaceutical Company Limited

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/14572

Key Takeaways - Orally Disintegrating Tablets Market Study

CNS diseases remain the primary area of application for orally disintegrating tablets. Researchers and healthcare providers are increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer's disease, schizophrenia, depressive disorders and others to increase the application of orally disintegrating tablets.
Formulation process of orally disintegrating tablets is usually patented by manufacturers depending on the technology employed during the production such as lyophilization, freeze drying, and floss formation. Many technologies such as ZYDIS®, LYOC® and QUICKSOLV® are dependent on freeze drying method.
Easy disintegration of orally disintegrating tablets in saliva within a few seconds and accuracy of dose as compared to liquid forms and chewable tablet are expected to increase the adoption of ODTs in diseases such as ulcers of throat.

Attributed to consumers facing swallowing problems, bitter taste of drugs, and patient incompliance, manufacturers are focusing to improve drug formulations. This would help them gain an edge in terms of innovation, further favoring the growth of orally disintegrating tablets market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/14572

Key Manufacturers Exploring New Business Models

The global orally disintegrating tablets market is fragmented with low entry barriers inspiring generic manufacturers to tap market opportunities in the form of ANDA, arising from the expiry of patent regime of approved drugs. For instance, Mylan N.V. launched Lansoprazole DR ODT, a generic version of Takeda's Prevacid® SoluTab DR ODT. The entry of The Himalaya Drug Company LTD. and Banyan Botanicals with new herbal ODT product offerings in next few years is expected to increase product lines and extension in ODTs market.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp

Report Inclusions

Persistence Market Research offers a unique perspective and actionable insights on the Orally Disintegrating Tablets landscape in its new study, presenting historical demand assessment from 2014 - 2018 and projections from 2019 - 2029 on the basis of drug class (anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-Parkinsonian drugs, anti-hypertensives, NSAIDS, anti-allergy drugs, proton pump inhibitors), disease indication (CNS diseases, GI diseases, allergy, CVS disorders), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), and five key regions.

Related Reports:

Allergy Shots Market - https://www.persistencemarketresearch.com/market-research/allergy-shots-market.asp

Uveitis Treatment Market - https://www.persistencemarketresearch.com/market-research/uveitis-treatment-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Computed Tomography to Drive The Orally Disintegrating Tablet Market here

News-ID: 2559735 • Views:

More Releases from Persistence Market Research

Microelectronic Medical Implants Market Size to Hit USD 98.5 Billion in 2032, expanding at a CAGR of 8.5% | PMR Report
Microelectronic Medical Implants Market Size to Hit USD 98.5 Billion in 2032, ex …
The microelectronic medical implants market plays a pivotal role in advancing modern healthcare by integrating electronics into medical devices to restore or enhance physiological functions. These implants are widely used in cardiology, neurology, orthopedics, and sensory assistance, including pacemakers, cochlear implants, neurostimulators, and insulin pumps. By offering precise monitoring, stimulation, and drug delivery, microelectronic implants significantly improve patient outcomes, quality of life, and long-term disease management. Request a Sample: https://www.persistencemarketresearch.com/samples/33122 According to
Dental Adhesives Market Worth US$ 4,052.8 Million By 2032, PMR Report
Dental Adhesives Market Worth US$ 4,052.8 Million By 2032, PMR Report
The dental adhesives market plays a critical role in modern dentistry by improving the durability, effectiveness, and esthetic outcomes of restorative and preventive dental procedures. Dental adhesives are extensively used in applications such as composite restorations, dental sealants, orthodontic bonding, and prosthodontics. They enhance adhesion between dental tissues and restorative materials, ensuring long-lasting results while minimizing microleakage, sensitivity, and secondary caries. Request a Sample: https://www.persistencemarketresearch.com/samples/33315 According to the latest study by Persistence
Wound Sprays Market Set to Soar to $694.5 Million by 2032 , Persistence Market Research,Inc
Wound Sprays Market Set to Soar to $694.5 Million by 2032 , Persistence Market R …
The wound sprays market plays a crucial role in modern healthcare by providing rapid, convenient, and effective solutions for wound management. Wound sprays are extensively used in hospitals, clinics, emergency care, and home healthcare settings to prevent infections, accelerate healing, and improve patient comfort. They are particularly valuable for cuts, abrasions, burns, surgical incisions, and chronic wounds. Request a Sample: https://www.persistencemarketresearch.com/samples/33306 According to the latest study by Persistence Market Research, The global
Surgical Instrument Tracking System Market Poised for 14.2% CAGR Growth by 2033
Surgical Instrument Tracking System Market Poised for 14.2% CAGR Growth by 2033
The surgical instrument tracking system market plays a pivotal role in enhancing the efficiency, safety, and accountability of surgical operations. These systems are widely deployed in hospitals, surgical centers, and clinics to manage surgical instruments, monitor their usage, and ensure sterilization compliance. By providing real-time tracking and inventory management, surgical instrument tracking systems reduce operational errors, prevent infections, and streamline surgical workflows. For More Information: https://www.persistencemarketresearch.com/market-research/surgical-instrument-tracking-system-market.asp According to the latest study by Persistence

All 5 Releases


More Releases for ODT

Phase 3 Clinical Trial for Major Depressive Disorder Treatment Market Begins 202 …
The Global Major Depressive Disorder Market size reached US$ 6.84 billion in 2024 and is expected to reach US$ 14.57 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. The Major Depressive Disorder Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and F …
Orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period. According to the US Food and Drug Administration (FDA), ODT's are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the forecast period is
Orally Disintegrating Tablet (ODT) Market Share 2021 Growth Challenges, Opportun …
The global orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). According to the US Food and Drug Administration (FDA), ODT’s are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the
Orally Dissolving Tablets (ODT) Excipient Market global outlook and forecast 202 …
The Global Orally Dissolving Tablets (ODT) Excipient Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Orally Dissolving Tablets (ODT) Excipient makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and
Investigation announced for Long-Term Investors in shares of Odonate Therapeutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Odonate Therapeutics, Inc.. Investors who are current long term investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ODT stocks follows a lawsuit filed against Odonate
Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics …
The Shareholders Foundation announced that a deadline is coming up on November 16, 2020 in the lawsuit filed for certain investors of Odonate Therapeutics, Inc. (NASDAQ: ODT) over alleged securities laws violations by Odonate Therapeutics, Inc. Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and there are strict and short deadlines running. Deadline: November 16, 2020. NASDAQ: ODT stockholders should contact the Shareholders Foundation at